BioPharma Dive - Latest News

The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.

Robert Plenge is leaving as part of a shift that will see the company merge together its R&D department in a bid to speed development and capitalize on new technologies. 

The agency is still recovering from a mass staff exodus last year that left it shorthanded. Here’s what it means for the industry.

The report comes amid escalating tensions between the U.S. and Germany over drug prices, with several large pharmaceutical companies responding by scaling back investments in the country.

The deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.